StockStory.org on MSN
The 5 most interesting analyst questions from Bio-Techne’s Q1 earnings call
Bio-Techne’s first quarter was marked by a negative market reaction, with revenue coming in below Wall Street expectations.
May 6 (Reuters) - Biotech firm Bio-Techne on Wednesday missed Wall Street estimates for third-quarter revenue, as cuts to U.S. academic funding weighed on demand for its drug-development products.
Life sciences company Bio-Techne (NASDAQ:TECH) fell short of the market’s revenue expectations in Q1 CY2026, with sales ...
The company's 10-K for fiscal year 2024 identifies certain factors that could cause the company's actual results to differ materially from those projected in the forward-looking statements made during ...
Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...
Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...
MINNEAPOLIS, Sept. 16, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has attained ISO 9001:2015 certification at its fetal bovine serum (FBS) and specialty media ...
Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the deal, Bio-Techne will pay ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...
RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results